Anas Alsaleh1, Jill K J Gaidos1,2, Le Kang3, John F Kuemmerle4. 1. Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University, P.O. Box 980341, Richmond, VA, 24298, USA. 2. McGuire VA Medical Center, Richmond, VA, USA. 3. Department of Biostatistics, Virginia Commonwealth University, Richmond, VA, USA. 4. Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University, P.O. Box 980341, Richmond, VA, 24298, USA. john.kuemmerle@vcuhealth.org.
Abstract
BACKGROUND: The association between preoperative use of infliximab and postoperative complications in patients with inflammatory bowel disease (IBD) is a subject of continued debate. Results from studies examining an association between the timing of last preoperative dose of infliximab and postoperative complications remain inconsistent. AIMS: To assess whether timing of last dose of infliximab prior to surgery affects the rate of postoperative complications in patients with Crohn's disease or ulcerative colitis. METHODS: Retrospective chart review of IBD patients who have undergone surgery while receiving therapy with infliximab was conducted. Forty-seven patients were included in the analysis. RESULTS: No significant association was found between timing of infliximab and the rate of postoperative complications. Age, gender, disease type, steroid use, preoperative status, surgery type, or surgeon type was not associated with increased rate of postoperative complications. CONCLUSION: Timing of last dose of infliximab does not affect the rate of postoperative complications in patients with Crohn's disease or ulcerative colitis.
BACKGROUND: The association between preoperative use of infliximab and postoperative complications in patients with inflammatory bowel disease (IBD) is a subject of continued debate. Results from studies examining an association between the timing of last preoperative dose of infliximab and postoperative complications remain inconsistent. AIMS: To assess whether timing of last dose of infliximab prior to surgery affects the rate of postoperative complications in patients with Crohn's disease or ulcerative colitis. METHODS: Retrospective chart review of IBDpatients who have undergone surgery while receiving therapy with infliximab was conducted. Forty-seven patients were included in the analysis. RESULTS: No significant association was found between timing of infliximab and the rate of postoperative complications. Age, gender, disease type, steroid use, preoperative status, surgery type, or surgeon type was not associated with increased rate of postoperative complications. CONCLUSION: Timing of last dose of infliximab does not affect the rate of postoperative complications in patients with Crohn's disease or ulcerative colitis.
Authors: Michael S Kasparek; Andreas Bruckmeier; Florian Beigel; Mario H Müller; Stephan Brand; Ulrich Mansmann; Karl-Walter Jauch; Thomas Ochsenkühn; Martin E Kreis Journal: Inflamm Bowel Dis Date: 2011-09-16 Impact factor: 5.325
Authors: Kweku A Appau; Victor W Fazio; Bo Shen; James M Church; Bret Lashner; Feza Remzi; Aaron Brzezinski; Scott A Strong; Jeffrey Hammel; Ravi P Kiran Journal: J Gastrointest Surg Date: 2008-08-15 Impact factor: 3.452
Authors: Mark Lazarev; Thomas Ullman; Wolfgang H Schraut; Kevin E Kip; Melissa Saul; Miguel Regueiro Journal: Inflamm Bowel Dis Date: 2010-05 Impact factor: 5.325
Authors: Susanna Meade; Kamal V Patel; Raphael P Luber; Dearbhaile O'Hanlon; Andra Caracostea; Polychronis Pavlidis; Sailish Honap; Cheran Anandarajah; Nyree Griffin; Sebastian Zeki; Shuvra Ray; Joel Mawdsley; Mark A Samaan; Simon H Anderson; Amir Darakhshan; Katie Adams; Andrew Williams; Jeremy D Sanderson; Miranda Lomer; Peter M Irving Journal: Aliment Pharmacol Ther Date: 2022-06-20 Impact factor: 9.524